Thank you for your interest in Totect. This product has been purchased by Biocodex, Inc. and is in the process of transition.
- Totect is currently not available. Biocodex has committed to establishing solutions to the longstanding product availability issues facing healthcare professionals.
- Biocodex is working diligently to reestablish availability and improve accessibility of Totect for the protection of patients undergoing chemotherapy. Totect is indicated for the treatment of anthracycline chemotherapy extravasation.
- If you need medical support, or wish to report an Adverse Event, please call the following number: 1-866-914-2922
- For other inquiries or general information, please call: 1-866-914-2922
Contraindications: None Warnings: Pregnancy Category D Precautions: TOTECT® is a cytotoxic drug. When administered to patients receiving anthracycline containing cytotoxic therapy, additive cytotoxicity may occur. Treatment with TOTECT® is associated with leukopenia, neutropenia, and thrombocytopenia. Hematological monitoring should be performed. Reversible elevations of liver enzymes may occur with dexrazoxane. Patients with Moderate or Severe Renal Insufficiency: Greater exposure to dexrazoxane may in occur in patients with compromised renal function. The TOTECT® dose should be reduced by 50% in patients with creatinine clearance values < 40mL/min. Dimethylsulfoxide (DMSO) should not be used in patients who are receiving dexrazoxane to treat anthracycline-induced extravasation. Laboratory Tests: Blood counts and liver enzymes should be monitored. Adverse Reactions: Dexrazoxane has been studied previously as a cytotoxic agent. Adverse reactions of nausea/vomiting, diarrhea, stomatitis, bone marrow suppression (neutropenia, thrombocytopenia), altered liver function (increased AST/ALT), and infusion site burning have been observed. These adverse reactions have been reversible. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.